Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Next Previous
Trial Profile

ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seladelpar (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Adverse reactions; Registrational
  • Acronyms ASSURE
  • Sponsors CymaBay Therapeutics; Gilead Sciences

Most Recent Events

  • 07 Nov 2025 According to a Gilead Sciences Media Release, data from this trial was presented at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD) 2025 in Washington, D.C. (November 7 to 11).
  • 23 Oct 2025 According to a Gilead Sciences Media Release, company to present data from this study in multiple oral and poster presentation at The Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C.
  • 07 May 2025 According to a Gilead Sciences Media Release, data from this trial were presented at the European Association for the Study of the Liver (EASL) Congress 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top